Allelic losses at chromosome 3p are seen in human papilloma virus 16 associated transitional cell carcinoma of the cervix

Gynecologic Oncology

Volumn 74, Issue 3, 1999, Pages 361-368

  Maitra, Anirban ^a   Wistuba, Ignacio I ^a   Gibbons, David ^a   Gazdar, Adi F ^a   Albores Saavedra, Jorge ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cervix; Chromosome 3; Chromosome 9; Human papilloma virus; P53; Transitional cell carcinoma

Indexed keywords

ARTICLE; CELL DIFFERENTIATION; CHROMOSOME 3P; CHROMOSOME 9; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CARCINOMA; VIRUS TYPING; WART VIRUS;

EID: 0032843151     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5489     Document Type: Article

References (59)

1. Robey SS, Silva EG, Gershenson DM, McLemore D, el-Naggar A, Ordonez NG: Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer 63:839-847, 1989
2. Gershenson DM, Silva EG, Mitchell MF, Atkinson EN, Wharton JT: Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol 168:1178-1185; discussion 1185-1187, 1993
3. Gershenson DM, Baker VV, Price JE, Hung MC, El-Naggar AK, Tortolero-Luna G, Silva EG: Molecular profile of advanced-stage transitional cell carcinoma of the ovary. Am J Obstet Gynecol 177:120-125, 1997
4. Albores-Saavedra J, Young RH: Transitional cell neoplasms (carcinomas and inverted papillomas) of the uterine cervix. A report of five cases. Am J Surg Pathol 19:1138-1145, 1995
5. Koenig C, Turnicky RP, Kankam CF, Tavassoli FA: Papillary squamotransitional cell carcinoma of the cervix: a report of 32 cases. Am J Surg Pathol 21:915-921, 1997
6. Lininger RA, Ashfaq R, Albores-Saavedra J, Tavassoli FA: Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation. Cancer 79:1933-1943, 1997
7. Spiegel GW, Austin RM, Gelven PL: Transitional cell carcinoma of the endometrium. Gynecol Oncol 60:325-230, 1996
8. Uehira K, Hashimoto H, Tsuneyoshi M, Enjoji M: Transitional cell carcinoma pattern in primary carcinoma of the fallopian tube. Cancer 72:2447-2456, 1993
9. Hovadhanakul P, Nuerenberger SP, Ritter PJ, Taylor HB, Cavanagh D: Primary transitional cell carcinoma of the fallopian tube associated with primary carcinomas of the ovary and endometrium. Gynecol Oncol 4:138-143, 1976
10. Thomason RW, Rush W, Dave H: Transitional cell carcinoma arising within a paratubal cyst: report of a case. Int J Gynecol Pathol 14:270-273, 1995
11. Harnden P, Allam A, Joyce AD, Patel A, Selby P, Southgate J: Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 27:169-174, 1995
12. Miettinen M: Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol 8:384-388, 1995
13. Weir MM, Bell DA, Young RH: Transitional cell metaplasia of the uterine cervix and vagina: an underrecognized lesion that may be confused with high-grade dysplasia. A report of 59 cases [see comments]. Am J Surg Pathol 21:510-517, 1997
14. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF: Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 57:3154-3158, 1997
15. Habuchi T, Devlin J, Elder PA, Knowles MA: Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 11:1671-1674, 1995
16. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CHd, Gonzalez-Zulueta M, Nichols PW, Skinner DG, Jones PA: Role of chromosome 9 in human bladder cancer. Cancer Res 53:4066-4070, 1993
17. Rader JS, Gerhard DS, O'Sullivan MJ, Li Y, Li L, Liapis H, Huettner PC: Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer 22:57-65, 1998
18. Larson AA, Kern S, Curtiss S, Gordon R, Cavenee WK, Hampton GM: High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res 57:4082-4090, 1997
19. Devlin J, Keen AJ, Knowles MA: Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene 9:2757-2760, 1994
20. Cordon-Cardo C, Reuter VE: Alterations of tumor suppressor genes in bladder cancer. Semin Diagn Pathol 14:123-132, 1997
21. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, Liotta LA: Laser capture microdissection: molecular analysis of tissue. Science 278:1481-1483, 1997
22. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, Gazdar AF: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma [published erratum appears in J Am Med Assoc 1995 Jun 28:273(24):1908]. J Am Med Assoc 273:558-563, 1995
23. Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, Stolz E, Herbrink P: Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 34:745-747, 1996
24. Thiberville L, Bourguignon J, Metayer J, Bost F, Diarra-Mehrpour M, Bignon J, Lam S, Martin JP, Nouvet G: Frequency and prognostic evaluation of 3p21-22 allelic losses in non-small-cell lung cancer. Int J Cancer 64:371-377, 1995
25. Fondon JW 3rd, Mele GM, Brezinschek RI, Cummings D, Pande A, Wren J, O'Brien KM, Kupfer KC, Wei MH, Lerman M, Minna JD, Garner HR: Computerized polymorphic marker identification: experimental validation and a predicted human polymorphism catalog. Proc Natl Acad Sci USA 95:7514-7519, 1998
26. Kishimoto Y, Sugio K, Hung JY, Virmani AK, McIntire DD, Minna JD, Gazdar AF: Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers [see comments]. J Natl Cancer Inst 87:1224-1229, 1995
27. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF: Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. J Am Med Assoc 279:1554-1559, 1998
28. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, et al.: p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180, 1992
29. Chu TY, Shen CY, Chiou YS, Lu JJ, Perng CL, Yu MS, Liu HS: HPV-associated cervical cancers show frequent allelic loss at 3p14 but no apparent aberration of FHIT mRNA. Int J Cancer 75:199-204, 1998
30. Guo Z, Wilander E, Sallstrom J, Ponten J: Deletion of chromosome 3p is an early event in malignant progression of cervical cancer. Anticancer Res 18:707-712, 1998
31. Kersemaekers AM, Hermans J, Fleuren GJ, van de Vijver MJ: Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. Br J Cancer 77:192-200, 1998
32. Wong YF, Chung TK, Cheung TH, Tam PO, Chang AM: Frequent loss of heterozygosity of chromosome 3 short arm detected by PCR-based microsatellite polymorphisms in cervical squamous cell carcinoma. Cancer Lett 115:161-164, 1997
33. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, et al.: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994
34. Simoneau AR, Spruck CH 3rd, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA: Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 56:5039-5043, 1996
35. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D: Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 55:5213-5216, 1995
36. Habuchi T, Luscombe M, Elder PA, Knowles MA: Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48:277-288, 1998
37. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA: Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 50:44-47, 1990
38. Cairns P, Tokino K, Eby Y, Sidransky D: Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 54:1422-1424, 1994
39. Wu Q, Possati L, Montesi M, Gualandi F, Rimessi P, Morelli C, Trabanelli C, Barbanti-Brodano G: Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9. Int J Cancer 65:840-846, 1996
40. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG: Allelotype of human bladder cancer. Cancer Res 54:531-538, 1994
41. Li M, Zhang ZF, Reuter VE, Cordon-Cardo C: Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol 149:229-235, 1996
42. Busby-Earle RM, Steel CM, Williams AR, Cohen B, Bird CC: p53 mutations in cervical carcinogenesis - low frequency and lack of correlation with human papillomavirus status. Br J Cancer 69:732-737, 1994
43. Kessis TD, Slebos RJ, Han SM, Shah K, Bosch XF, Munoz N, Hedrick L, Cho KR: p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol 143:1398-1405, 1993
44. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, et al.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784-788, 1994
45. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, Terada M: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52:1393-1398, 1992
46. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP: Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72:1272-1280, 1993
47. Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiere A, Clough K, Favre M, Pouillart P, Sastre-Garau X: Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol 16:2613-2619, 1998
48. Howley PM: Role of the human papillomaviruses in human cancer. Cancer Res 51:5019s-5022s, 1991
49. van Beurden M, ten Kate FW, Tjong AHSP, de Craen AJ, van der Vange N, Lammes FB, ter Schegget J: Human papillomavirus DNA in multicentric vulvar intraepithelial neoplasia. Int J Gynecol Pathol 17:12-16, 1998
50. Buscema J, Naghashfar Z, Sawada E, Daniel R, Woodruff JD, Shah K: The predominance of human papillomavirus type 16 in vulvar neoplasia. Obstet Gynecol 71:601-606, 1988
51. Wiener JS, Walther PJ: A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: polymerase chain reaction-based analysis of multiple histological types. J Urol 151:49-53, 1994
52. O'Leary JJ, Landers RJ, Crowley M, Healy I, O'Donovan M, Healy V, Kealy WF, Hogan J, Doyle CT: Human papillomavirus and mixed epithelial tumors of the endometrium [see comments]. Hum Pathol 29:383-389, 1998
53. Mvula M, Iwasaka T, Iguchi A, Nakamura S, Masaki Z, Sugimori H: Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? J Urol 155:471-474, 1996
54. Knowles MA: Human papillomavirus sequences are not detectable by Southern blotting or general primer-mediated polymerase chain reaction in transitional cell tumours of the bladder. Urol Res 20:297-301, 1992
55. Noel JC, Thiry L, Verhest A, Deschepper N, Peny MO, Sattar AA, Schulman CC, Haot J: Transitional cell carcinoma of the bladder: evaluation of the role of human papillomaviruses. Urol 44:671-675, 1994
56. Chang F, Lipponen P, Tervahauta A, Syrjanen S, Syrjanen K: Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction. J Urol 152:1429-1433, 1994
57. Lininger RA, Wistuba I, Gazdar A, Koenig C, Tavassoli FA, Albores-Saavedra J: Human papillomavirus type 16 is detected in transitional cell carcinomas and squamotransitional cell carcinomas of the cervix and endometrium. Cancer 83:521-527, 1998
58. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI, Glover TW: FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 5:187-195, 1996
59. Cannizzaro LA, Durst M, Mendez MJ, Hecht BK, Hecht F: Regional chromosome localization of human papillomavirus integration sites near fragile sites, oncogenes, and cancer chromosome breakpoints. Cancer Genet Cytogenet 33:93-98, 1988